Best First-Line Medication for Primary Insomnia
For adults with primary insomnia who have failed sleep hygiene measures, choose your medication based on the specific sleep problem: use eszopiclone or zolpidem for both sleep onset and maintenance issues, zaleplon or ramelteon for sleep onset only, or suvorexant or doxepin for sleep maintenance only. All recommendations carry equal weak strength, so selection depends on the patient's predominant complaint 1.
Medication Selection Algorithm
For Sleep Onset AND Maintenance Problems:
- Eszopiclone (2-3 mg) - addresses both falling asleep and staying asleep 1
- Zolpidem (10 mg) - addresses both falling asleep and staying asleep 1
- Temazepam (15 mg) - addresses both problems but is a benzodiazepine with more concerns 1
For Sleep Onset Problems Only:
- Zaleplon (10 mg) - shortest half-life, minimal next-day effects 1
- Ramelteon (8 mg) - melatonin receptor agonist with excellent safety profile, particularly good for older adults 1, 2
- Triazolam (0.25 mg) - benzodiazepine, use cautiously 1
For Sleep Maintenance Problems Only:
- Suvorexant (10-20 mg) - orexin receptor antagonist, newer mechanism 1
- Doxepin (3-6 mg) - low-dose tricyclic, minimal anticholinergic effects at these doses 1
Critical Evidence Context
The 2017 American Academy of Sleep Medicine guidelines 1 provide the most authoritative framework, though all pharmacologic recommendations carry only WEAK strength. This reflects inherent limitations in the evidence base: industry funding bias, small trial numbers per agent, and data heterogeneity 1. The weakness of recommendations does NOT mean these medications are ineffective—it reflects uncertainty in the published evidence quality, not clinical utility 1.
Meta-analyses show small to moderate effect sizes for both benzodiazepines and non-benzodiazepine receptor agonists (Z-drugs), with Z-drugs having superior safety profiles 1. Non-benzodiazepine receptor agonists (eszopiclone, zaleplon, zolpidem) have become first-line agents due to proven efficacy, reduced side effects, and less addiction concern compared to traditional benzodiazepines 3.
Medications to AVOID
The AASM explicitly recommends AGAINST these commonly used agents 1:
- Trazodone - insufficient evidence despite widespread off-label use
- Diphenhydramine - anticholinergic effects, tolerance develops rapidly
- Melatonin (over-the-counter formulations) - inconsistent evidence
- Tiagabine - insufficient evidence
- Valerian - insufficient evidence
- L-tryptophan - insufficient evidence
Special Considerations for Older Adults
In geriatric populations, ramelteon emerges as a particularly valuable first-line option due to minimal adverse effects, no dementia risk, and efficacy for sleep-onset latency 2. Benzodiazepines should be discouraged in older adults due to fall risk, fractures, and cognitive impairment 2. While non-BzRAs have improved safety over benzodiazepines, they still carry risks of dementia, serious injury, and fractures in elderly patients 2.
Suvorexant shows promise in older adults with improved sleep maintenance and mild adverse effects, though residual daytime sedation can occur 2.
Common Pitfalls to Avoid
Don't prescribe antihistamines routinely - tolerance develops quickly and anticholinergic burden is problematic, especially in older adults 1, 2
Don't use trazodone as first-line - despite its popularity in clinical practice, evidence doesn't support its use 1, 4
Don't use benzodiazepines long-term - reserve for short-term use only due to dependence, withdrawal, and adverse effects 5, 2
Don't ignore the sleep pattern - matching medication to whether the problem is sleep onset vs. maintenance vs. both is critical for optimal outcomes 1
Avoid alcohol as a sleep aid - potential for abuse and disrupts sleep architecture 5
Practical Implementation
Recent evidence suggests dual orexin receptor antagonists (suvorexant) are particularly effective for sleep maintenance or mixed onset/maintenance problems 6. The 2024 update notes that while benzodiazepines and Z-drugs remain commonly prescribed, they should be avoided when possible due to short- and long-term risks 6.
For patients requiring long-term treatment, newer-generation non-benzodiazepines (zolpidem, zaleplon, eszopiclone) and ramelteon have better safety profiles making them superior choices over traditional benzodiazepines 5.
The evidence consistently emphasizes that cognitive behavioral therapy for insomnia (CBT-I) remains the gold standard and should be attempted before or alongside pharmacotherapy 1, 6. When medications are necessary, they should generally be prescribed for short periods with frequency and duration customized to individual circumstances 5.